Nurix Therapeutics, Inc.
NRIX · NASDAQ
11/30/2024 | 11/30/2023 | 11/30/2022 | 11/30/2021 | |
|---|---|---|---|---|
| Market Cap | $1,484 | $338 | $602 | $1,236 |
| - Cash | $110 | $55 | $64 | $81 |
| + Debt | $28 | $31 | $12 | $13 |
| Enterprise Value | $1,402 | $314 | $550 | $1,169 |
| Revenue | $55 | $77 | $39 | $30 |
| % Growth | -29.1% | 99.3% | 29.8% | – |
| Gross Profit | -$167 | -$112 | -$146 | -$87 |
| % Margin | -306.3% | -145.7% | -377.6% | -291.4% |
| EBITDA | -$205 | -$149 | -$180 | -$116 |
| % Margin | -375.8% | -193.4% | -465.3% | -389.6% |
| Net Income | -$194 | -$144 | -$180 | -$117 |
| % Margin | -354.9% | -187% | -466.9% | -393.9% |
| EPS Diluted | -2.88 | -2.65 | -3.71 | -2.73 |
| % Growth | -8.7% | 28.6% | -35.9% | – |
| Operating Cash Flow | -$173 | -$81 | -$160 | -$84 |
| Capital Expenditures | -$9 | -$8 | -$12 | -$6 |
| Free Cash Flow | -$182 | -$90 | -$172 | -$90 |